How is Tesamorelin administered?
This describes how Tesamorelin is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a once daily schedule, generally over 12-26 weeks typical. Specific dosing is individual and beyond general information, and human evidence for Tesamorelin is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Once daily
- Cycle length: 12-26 weeks typical
- Half-life: ~30 minutes
References
- Tesamorelin for HIV-associated lipodystrophy — Falutz J et al., NEJM, 2007
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial — Stanley TL et al., JAMA, 2014
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data — Falutz J et al., Journal of Clinical Endocrinology & Metabolism, 2010
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Tesamorelin
Full Tesamorelin breakdownTesamorelin what it's used forTesamorelin side effectsTesamorelin mistakes to avoidTesamorelin who should avoid itTesamorelin half-lifeTesamorelin how long to workTesamorelin legal statusTesamorelin how it workscjc 1295 vs tesamorelinaod 9604 vs tesamorelinipamorelin vs tesamorelintesamorelin vs sermorelinAsk the AI Coach
Last updated 2026-06-15.